Treatment of Idiopathic Perifoveal Telangiectasia (IPT) With Open-Label Anecortave Acetate (15mg.).

Launched by MANHATTAN EYE, EAR & THROAT HOSPITAL · Sep 13, 2005

Keywords

ClinConnect Summary

In this open-label pilot study, an initial patient, which presented with IPT and SRN, was treated with promising success and five additional patients were then recruited. So this is a report on six eyes of the first six patients with this disease who presented in our practice. The Food and Drug Administration (FDA) granted our site permission to enroll these patients. While anecortave acetate has not yet been approved by the FDA, it has been used in phase 2/3 trials for the treatment of AMD. An informed consent was obtained from each patient. IRB approval was obtained from Manhattan Eye, Ea...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Clinical diagnosis of patients with Idiopathic Perifoveal Telangiectasia(IPT).
• • 2. Patients must be 18 years of age or older to receive treatment.
• • 3. Visual acuity of 20/30 to 20/320 Study Eye on the ETDRS visual acuity chart.
• • 4. Visual acuity of 20/800 or better Fellow Eye on the ETDRS visual acuity chart .
• Exclusion Criteria:
• • 1. Patient with significantly compromised visual acuity in the study eye due to concomitant ocular conditions.
• • 2. Patients who have undergone intraocular surgery within last 2 months.
• • 3. Patient participating in any other investigational drug study.
• • 3.Use of an investigational drug or treatment related or unrelated to their condition within 30 days prior to receipt of study medication.
• • 4.Inability to obtain photographs to document CNV (including difficulty with venous access).
• • 5.Patient with significant liver disease or uremia. 6.Patient with known adverse reaction to fluorescein and indocyanine green or iodine.
• • 7.Patient has a history of any medical condition which would preclude scheduled visits or completion of study.
• • 8.Patient has had insertion of scleral buckle in the study eye. 9.Patient has received radiation treatment 10.Patient is on anticoagulant therapy with the exception of aspirin 11.Patient is pregnant or nursing.